Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Safety Profile of Standard and Booster Covid-19 Vaccines in Physicians in Quito-Ecuador. A Cross-Sectional Study

Nancy Jeanneth Flores-Lastra
,
Josue David Rivadeneira-Dueñas
* ORCID logo ,
Luis Ernesto Fuenmayor-González
ORCID logo ,
Glenda Guayasamín-TIpanta
,
Michelle Jácome-García
,
Tamara Otzen
,
Carlos Manterola
Version 1 : Received: 24 January 2023 / Approved: 25 January 2023 / Online: 25 January 2023 (03:50:52 CET)

A peer-reviewed article of this Preprint also exists.

Flores-Lastra, N.; Rivadeneira-Dueñas, J.; Fuenmayor-González, L.; Guayasamín-Tipanta, G.; Jácome-García, M.; Otzen, T.; Manterola, C. Safety Profile of Homologous and Heterologous Booster COVID-19 Vaccines in Physicians in Quito-Ecuador: A Cross-Sectional Study. Vaccines 2023, 11, 676. Flores-Lastra, N.; Rivadeneira-Dueñas, J.; Fuenmayor-González, L.; Guayasamín-Tipanta, G.; Jácome-García, M.; Otzen, T.; Manterola, C. Safety Profile of Homologous and Heterologous Booster COVID-19 Vaccines in Physicians in Quito-Ecuador: A Cross-Sectional Study. Vaccines 2023, 11, 676.

Abstract

More than 600 Healthcare workers died due to COVID-19 infection until January 2022 in Ecuador. Even though the COVID-19 vaccines are safe, local, and systemic reactions were reported among physicians. This study aims to analyze the Adverse events (AEs) of COVID-19 vaccines with an emphasis on homologous and heterologous booster doses. An electronic survey was performed in Quito- Ecuador, directed to physicians who were vaccinated with the three doses of COVID-19 vaccines. 210 participants were analyzed after administering any doses of the vaccines. At least one AE was identified in 60.0% (126/210) of the sample after the first dose, 52.40% (110/210) after the second dose, and 75.2% (158/210) after the booster dose. The most frequent AEs were localized pain, myalgia, headache, and fever. At least one drug was used in 44.3% of the population after the first dose, 37.1% after the second dose, and 63.8% in the booster dose. Heterol-ogous booster produces more AEs compared with homologous booster (80.1% vs. 53.8%), and 77.3% of participants reported that interfered with daily activities. Similar studies agree that reactogenicity occurs mainly with heterologous vaccination compared to ho-mologous vaccination. This situation affected physicians’ performance in daily activities and led them to use medication for the symptoms

Keywords

COVID-19 Vaccines; BNT162 Vaccine; ChAdOx1 nCoV-19; Side Effects and Adverse Reactions; Booster Immunizations; COVID-19; SARS-CoV-2

Subject

Medicine and Pharmacology, Pharmacology and Toxicology

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.